Why Is ARCUTIS BIOTHERAPEUT (ARQT) Stock Moving Today?

Arcutis Biotherapeutics stock (ARQT) rose 7.39% to $26.30 on Wednesday. The primary driver was the presentation of new clinical data for its ZORYVE (roflumilast) portfolio at the European Academy of Dermatology and Venereology congress. The data highlighted rapid itch relief and broad efficacy across atopic dermatitis, psoriasis, and seborrheic dermatitis.

What Happened

Arcutis presented results from the Phase 2 INTEGUMENT-INFANT trial, which evaluated ZORYVE cream 0.05% in infants aged 3 to under 24 months. The study reported a 34.4% vIGA-AD Success rate at Week 4, a significant finding given the limited treatment options currently available for this patient population. The company also shared new analyses from the ARRECTOR and DERMIS-1/2 trials, further supporting the drug’s utility.

In related regulatory news, Arcutis Canada secured Health Canada approval for roflumilast cream in pediatric atopic dermatitis patients. Analysts responded positively to the data. Morgan Stanley maintained its Overweight rating on the stock and raised its price target to $38. Guggenheim also maintained a Buy rating and raised its price target to $38.

What The Data Shows

The stock opened at $24.70, a 0.9% gap up from the prior close of $24.49. It reached a session high of $26.41 at 11:55 AM ET before settling near $26.38. Volume was 0.4 million shares, which is 0.2 times the three-month daily average. The stock printed 42 fresh 52-week highs on October 9, 2026, extending its recent upward momentum.

Fundamentals show a market cap of $3.0 billion and a trailing P/E of 113.7. Revenue grew 76.1% over the trailing twelve months, and the net margin stands at 6.1%. The stock has a beta of 1.58 and trades within a 52-week range of $19.30 to $31.77. Recent insider activity has been predominantly selling, with 11 sales totaling $2.1 million in the last 90 days and no buys recorded.

What To Watch

Investors will monitor how the market digests the pediatric approval in Canada and the broader ZORYVE data. The upcoming earnings date is not provided in the current data set, so attention will likely remain on analyst price target revisions and further regulatory updates.